- Asked by: Elaine Smith, MSP for Central Scotland, Scottish Labour
-
Date lodged: Tuesday, 28 January 2020
-
Current Status:
Answered by Joe FitzPatrick on 19 February 2020
To ask the Scottish Government what steps it is taking to ensure that as many women (a) carers and (b) with asthma as possible engage with the consultation on its draft Respiratory Care Action Plan.
Answer
Throughout the development of the Draft Respiratory Care Action Plan (Plan) for Scotland, we have engaged with stakeholders across the respiratory community and third sector, including the British Lung Foundation and Chest Heart and Stroke Scotland, to ensure that the patient voice was heard.
The draft Plan sets out our commitments for driving improvements in the diagnosis, care, treatment and support of people living with respiratory conditions, including those living with asthma in Scotland.
We want to hear experiences, good and bad, and learn more about what we could do differently, and what we must do better to make the difference people need which us why we will continue to engage with stakeholders throughout the consultation period. We would encourage as many people as possible to respond. in order to help develop and shape the final Respiratory Care Action Plan for Scotland.
- Asked by: Elaine Smith, MSP for Central Scotland, Scottish Labour
-
Date lodged: Tuesday, 28 January 2020
-
Current Status:
Answered by Joe FitzPatrick on 19 February 2020
To ask the Scottish Government what consideration it is giving to the use of preventative, as opposed to reactive, treatments to reduce the death rate from asthma.
Answer
Prevention is a key priority in our consultation on the draft Respiratory Care Action Plan for Scotland. We know that reducing the risk of respiratory conditions including asthma, means reducing or avoiding exposure to common risk factors. We have set out ambitious aims to tackle the health implications in respect of smoking, clean air, healthy weight and the importance of vaccinations. Our key plans can be found at: A healthier future: Scotland’s diet and healthy weight delivery plan , Raising Scotland's tobacco-free generation: our tobacco control action plan 2018 and Cleaner Air for Scotland: the road to a healthier future .
- Asked by: Elaine Smith, MSP for Central Scotland, Scottish Labour
-
Date lodged: Thursday, 30 January 2020
-
Current Status:
Answered by Joe FitzPatrick on 19 February 2020
To ask the Scottish Government whether it will introduce a statutory time limit for return chronic pain appointments similar to that in place for new patients, in light of figures released under freedom of information, which record that clinics dealt with 20,117 new and around 40,000 return appointments in 2018.
Answer
I refer the member to the answer to question S4W-30489 on 21 March 2016. All answers to written parliamentary questions are available on the Parliament’s website, the search facility for which can be found at http://www.parliament.scot/parliamentarybusiness/28877.aspx .
- Asked by: Elaine Smith, MSP for Central Scotland, Scottish Labour
-
Date lodged: Thursday, 30 January 2020
-
Current Status:
Answered by Joe FitzPatrick on 19 February 2020
To ask the Scottish Government, in light of there being no statutory waiting time for return chronic pain patient appointments, what analysis it has carried out of the waiting times being experienced by people requiring such appointments.
Answer
I refer the member to the answer to question S5W-27155 on 19 February 2020. All answers to written parliamentary questions are available on the Parliament’s website, the search facility for which can be found at http://www.parliament.scot/parliamentarybusiness/28877.aspx .
- Asked by: Elaine Smith, MSP for Central Scotland, Scottish Labour
-
Date lodged: Friday, 13 December 2019
-
Current Status:
Answered by Jeane Freeman on 13 January 2020
To ask the Scottish Government who determines the dosage, e.g. 5mg, 10mg or 20mg, of liothyronine (T3) in tablets that can be sourced by pharmacists for people with an under-active thyroid.
Answer
Pharmaceutical manufacturers are responsible for developing medicine, including determining the strength/dose, formulation and recommendations on appropriate dosages/quantity to be taken. Pharmaceutical companies invest in and undertake extensive research into developing and testing the safety, quality and efficacy of medicines. All medicines must be fully researched and tested before they can be licensed and prescribed to patients across NHSScotland. The licencing of medicines is a reserved matter for the UK Government. When a medicine is no longer in patent, it can be manufactured as a generic by any other pharmaceutical manufacturer.
- Asked by: Elaine Smith, MSP for Central Scotland, Scottish Labour
-
Date lodged: Thursday, 19 December 2019
-
Current Status:
Answered by Joe FitzPatrick on 9 January 2020
To ask the Scottish Government whether GPs can choose not to prescribe drugs to people who are being seen by an endocrinologist because of cost reasons.
Answer
Decisions by GPs on drugs to prescribe are based on safety, clinical effectiveness (efficacy) and cost effectiveness which is a clinical judgement. A prescriber will consider the clinical advice provided by the specialist when making the final decision about treatment for which they are responsible.
- Asked by: Elaine Smith, MSP for Central Scotland, Scottish Labour
-
Date lodged: Thursday, 19 December 2019
-
Current Status:
Answered by Joe FitzPatrick on 9 January 2020
To ask the Scottish Government under what circumstances GPs can choose not to prescribe drugs that are available on their NHS board's formulary.
Answer
The choice of drug to prescribe from a local formulary list, or to prescribe off-formulary, is a clinical decision which will be taken in consultation with the patient.
- Asked by: Elaine Smith, MSP for Central Scotland, Scottish Labour
-
Date lodged: Friday, 13 December 2019
-
Current Status:
Answered by Joe FitzPatrick on 9 January 2020
To ask the Scottish Government what information it has on the impact of the availability of liothyronine (T3) on people with an under-active thyroid.
Answer
The Scottish Government is supportive of the guidelines published by the British Thyroid Association in 2015. These are that T4 remains the treatment of choice in hypothyroidism. However, each Health Board in Scotland has confirmed that they are committed to clinicians initiating and continuing T3 where it is safe and clinically appropriate to do so, as agreed with an NHS consultant who specialises in endocrinology.
- Asked by: Elaine Smith, MSP for Central Scotland, Scottish Labour
-
Date lodged: Friday, 13 December 2019
-
Current Status:
Answered by Joe FitzPatrick on 9 January 2020
To ask the Scottish Government what its position is on whether people who require liothyronine (T3) medication should have to purchase this from overseas due to a lack of availability in Scotland.
Answer
The Scottish Government does not support importing any medicine, whether licenced or not, from abroad for medical use. All Health Boards in Scotland have confirmed that they are committed to:
1. a holistic and safe review of patients prescribed T3 which is undertaken by a healthcare professional based on the needs of the individual patient.
2. clinicians initiating and continuing T3 where it is safe and clinically appropriate to do so, as agreed with a NHS consultant who specialises in endocrinology.
- Asked by: Elaine Smith, MSP for Central Scotland, Scottish Labour
-
Date lodged: Friday, 13 December 2019
-
Current Status:
Answered by Jeane Freeman on 8 January 2020
To ask the Scottish Government what information it has on whether pharmaceutical companies produce various dosages, e.g. 5mg, 10mg or 20mg, of liothyronine (T3) medication, and what its position is on whether these should be made available to people with an under-active thyroid.
Answer
Liothyronine (T3) is licenced and available for use in the UK in 5 microgram, 10 microgram and 20 microgram strengths.
All medicines are prescribed based on clinical need. Doctors and other prescribers should always discuss treatment options with individuals. Prescribing decisions are based on national clinical guidelines which outline recommendations for effective practice based on current evidence.